三阴性乳腺癌用药进展  

Progress in Medications for Triple Negative Breast Cancer

作　　者：汪立刚[1] 文原梅 周亮[1] WANG Ligang;WEN Yuanmei;ZHOU Liang(Xiaoshan Hospital of Traditional Chinese Medicine,Hangzhou 311201,China;Innovation Institute for Artificial Intelligent in Medicine,Zhejiang University,Hangzhou 310018,China)

机构地区：[1]杭州市萧山区中医院,杭州311201 [2]浙江大学智能创新药物研究院,杭州310018

出　　处：《中国现代应用药学》2022年第11期1509-1516,共8页Chinese Journal of Modern Applied Pharmacy

摘　　要：三阴性乳腺癌是缺乏雌激素受体、孕激素受体和人类表皮生长因子受体-2的特殊类型的乳腺癌,相比其他乳腺癌亚型,其临床特征为预后较差、高侵袭性、高转移性以及高复发率。目前三阴性乳腺癌的早期治疗手段主要为蒽环类和紫杉烷类化学疗法,但容易产生耐药性;而且三阴性乳腺癌对一些现有的靶向药物和内分泌治疗药物敏感性也不高。因此本文在介绍目前三阴性乳腺癌涉及的临床用药的基础上,还对联合用药、新药研发进展作简要综述,为今后的用药提供思路。Triple-negative breast cancer is a special type of breast cancer that lacks expression of oestrogen receptors,progesterone receptor,human epidermal growth factor receptor-2.Compared with other breast cancer subtypes,triple-negative breast cancer generally has the clinical characteristic of poorer prognosis,higher aggressiveness,higher metastatic and higher rates of relapse.The treatment of triple-negative breast cancer in early stage has primarily consisted of anthracycline and taxane chemotherapy in recent years,however it is prone to drug resistance.Moreover,certain targeted medicines and endocrine treatment agents are not highly sensitive against triple-negative breast cancer.Therefore,this article briefly discusses the development of combination medications and novel therapies to provide suggestions for future medications,in addition to introducing the current clinical medications used in triple-negative breast cancer.

关 键 词：三阴性乳腺癌 化疗药物 靶向治疗药物 免疫治疗药物 用药策略 

分 类 号：R737.9[医药卫生—肿瘤]